10-Q: Galectin Therapeutics Reports Q1 2025 Results, NAVIGATE Trial Data Analysis Continues

Galectin Therapeutics reports its Q1 2025 financial results and continues to analyze data from the NAVIGATE clinical trial for belapectin.

Summary

• Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2025.
• The company is focused on developing therapies for fibrotic disease and cancer by targeting galectin proteins.
• A key focus is on belapectin (GR-MD-02), a galectin-3 inhibitor, for treating NASH cirrhosis and certain cancer indications.
• The company completed randomizations totaling 357 patients in the NAVIGATE trial, a Phase 2b/3 clinical trial.
• Top-line results from the NAVIGATE trial were presented in December 2024, with further data analysis expected in the second quarter of 2025.
• In the intent-to-treat population, the incidence of varices was reduced by 43.2% in the belapectin 2 mg/kg dose group vs placebo, but the composite endpoint did not reach statistical significance.
• In the per-protocol population, the incidence of varices was reduced by 49.3% in the belapectin 2 mg/kg dose group (p-value < 0.05).
• Further analysis of U.S. patients in the NAVIGATE trial showed a significant reduction of 68.1% (p=0.02) in the incidence of varices in patients treated with belapectin 2 mg vs placebo.
• The company believes there is sufficient cash, including availability of the two lines of credit, to fund currently planned operations through August 2025.
• The net loss applicable to common stockholders was $(9,605,000) or $(0.15) per share compared to $(11,497,000) or $(0.19) per share for the three months ended March 31, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are some positive aspects, such as the safety profile of belapectin and the reduction in net loss, the company is still operating at a loss and requires additional funding. The NAVIGATE trial results were mixed, with statistical significance only achieved in certain subgroups.

Positives

• The safety profile of belapectin remains highly encouraging with incidence of adverse events and serious adverse events comparable across the three cohorts.
• Rates of discontinuation, adverse events (AEs), and serious adverse events (SAEs) were comparable to placebo, with no drug-related SAEs reported in the NAVIGATE trial.
• Net loss decreased from $(11,497,000) to $(9,605,000) year over year.
• The company has access to $11 million remaining under two lines of credit provided by its chairman.

Negatives

• The company has operated at a loss since its inception and anticipates that losses will continue for the foreseeable future.
• The company believes there is sufficient cash, including availability of the two lines of credit, to fund currently planned operations through August 2025.
• The company will require more cash to fund its operations after August 2025.
• In the intent-to-treat population, the incidence of varices was reduced by 43.2% in the belapectin 2 mg/kg dose group vs placebo, but the composite endpoint did not reach statistical significance.

Risks

• The company's early stage of development poses risks.
• The company has incurred significant operating losses since its inception and cannot assure revenue or profit.
• The company is dependent on additional outside capital.
• The company may be unable to enter into strategic partnerships.
• There are uncertainties related to litigation, technology, and clinical trials.
• The company may be unable to demonstrate the efficacy and safety of its product candidates.
• The company may be unable to improve upon, protect, and/or enforce its intellectual property.
• The company is subject to extensive and costly regulation by the FDA and foreign regulatory authorities.
• Competition and stock price volatility in the biotechnology industry are risks.
• Limited trading volume for the company's stock and concentration of ownership are risks.

Future Outlook

The Company believes there is sufficient cash, including availability of the two lines of credit, to fund currently planned operations through August 2025. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions.

Management Comments

• Management believes that the prevention of esophageal varices may represent a clinically relevant measure of clinical efficacy in patients with NASH cirrhosis.
• Management believes that the data, taken together with the observed favorable safety and tolerability of the combination, provide a rationale to move the belapectin program in oncology forward.

Industry Context

Galectin Therapeutics is operating in the competitive biopharmaceutical industry, specifically targeting fibrotic diseases and cancer. The company's focus on galectin-3 inhibition aligns with the growing interest in immunotherapies and targeted treatments. The success of belapectin could position the company as a key player in the NASH cirrhosis and immuno-oncology markets.

Comparison to Industry Standards

• Galectin Therapeutics is developing belapectin for NASH cirrhosis, a space with significant unmet need.
• Companies like Intercept Pharmaceuticals and Genfit have also pursued NASH treatments, but with different mechanisms of action.
• The NAVIGATE trial results, particularly the reduction in varices in the per-protocol population and the U.S. subgroup, are promising but need further validation.
• The company's immuno-oncology program, combining belapectin with checkpoint inhibitors, is similar to approaches being explored by other companies like Merck (Keytruda) and Bristol-Myers Squibb (Yervoy).
• The company's cash position and ability to secure additional funding will be critical for continued development.

Related Party Transactions

• Richard E. Uihlein, the company's chairman, has provided convertible notes and lines of credit to the company.

Stakeholder Impact

• Shareholders: The mixed results of the NAVIGATE trial and the need for additional funding could impact shareholder value.
• Employees: The company's ability to secure funding will impact job security and future growth opportunities.
• Patients: The development of belapectin could provide a new treatment option for NASH cirrhosis and cancer.
• Creditors: The company's ability to repay its debts depends on its ability to generate revenue or secure additional funding.

Next Steps

• The Company continues to analyze trial data and expects to report additional information on specific biomarkers in the second quarter of 2025.
• The Company continues to analyze data from approximately 55 patients that completed 36 months of treatment prior to the ending of the trial in February 2025.
• The Company is reviewing options for financing this trial which will determine when such trial could commence.

Key Dates

Keywords

belapectin, NASH, cirrhosis, galectin-3, clinical trial, fibrosis, cancer, NAVIGATE, biopharmaceutical, therapeutics